Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy

Opus Genetics, Inc.

2025-Q1 EPS reported -$0.24 revenue$4,370,000

Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.
Cash and equivalents $41.8M; management expects runway into Q2 2026.
License revenue from Viatris was $4.4M, up from $1.7M YoY, primarily R&D reimbursement.
OPGx-LCA5 Phase 1/2 data at ARVO show durable efficacy at 12 months; pediatric cohort enrollment started.
Topline data for LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials expected mid-2025 and H1 2025, respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.